Algorae Pharmaceuticals Limited is an Australian biotechnology company specializing in the research, development, and commercialization of advanced pharmaceuticals, with a distinct focus on leveraging artificial intelligence in drug discovery. The company's core initiatives center around the development of therapeutic solutions for complex and unmet medical needs, most notably neurodegenerative conditions such as dementia, Alzheimer's disease, cardiovascular diseases like hypertension, and Parkinson’s disease. Its proprietary platform, AlgoraeOS, integrates artificial intelligence protocols and big data analytics to rapidly identify and evaluate novel drug candidates, including unique fixed-dose combinations and repurposed pharmaceuticals. The therapeutic pipeline features assets such as AI-116, a compound targeting dementia, AI-168 for cardiovascular conditions, and NTCELL, an encapsulated cell therapy for Parkinson’s disease. Originally founded as Living Cell Technologies Limited in 1987 and now headquartered in Melbourne, the company collaborates with leading research institutions, aiming to accelerate drug development and improve patient outcomes. Algorae Pharmaceuticals Limited represents a growing intersection of biotechnology and AI in medical research, shaping innovative pathways in the healthcare sector.